Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b53)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of the anthracycline daunorubicin and the antimetabolite cytarabine in a fixed 1:5 molar ratio. This formulation is designed to optimize the synergistic delivery of the two agents to leukemia cells while minimizing systemic toxicity. Daunorubicin acts by intercalating into DNA and inhibiting topoisomerase II, while cytarabine is a pyrimidine analog that inhibits DNA polymerase and incorporates into DNA, leading to chain termination. It was developed by Celator Pharmaceuticals (now Jazz Pharmaceuticals) and is primarily indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- daunorubicin and cytarabine liposomeliposomal daunorubicin and cytarabine
02
Targets
POLA1 (DNA polymerase alpha)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b53).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin + cytarabine) (Jazz Pharmaceuticals plc, 041b53).